Title : Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.

Pub. Date : 2020 Aug

PMID : 32673127






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 AREAS COVERED: Data from recent studies indicate that most patients relapsing on ibrutinib have mutations in BTK or PLCG2. ibrutinib phospholipase C gamma 2 Homo sapiens
2 There is downstream gain of function of BCR signaling with PLCG2 mutations allowing continued cell proliferation despite inhibition of BTK by ibrutinib. ibrutinib phospholipase C gamma 2 Homo sapiens